Clinical Trial Update: A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BID insulin degludec/insulin aspart versus once-daily insulin degludec with mealtime insulin aspart in type 2 diabetes patients needing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoLog (insulin aspart)
• Ryzodeg (insulin degludec/insulin aspart)
• Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-11-17